Ankit Mahadevia - Feb 5, 2025 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Director
Signature
/s/ Maegan Deare, Attorney-in-Fact for Ankit Mahadevia
Stock symbol
SPRO
Transactions as of
Feb 5, 2025
Transactions value $
-$53,991
Form type
4
Date filed
2/5/2025, 08:30 PM
Previous filing
Aug 29, 2024
Next filing
Jun 16, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Sale -$10.9K -14K -1.84% $0.78 745K Feb 5, 2025 Direct F1, F2
transaction SPRO Common Stock Sale -$43.1K -55.3K -7.42% $0.78 690K Feb 5, 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
F2 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
F3 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.